GeoVax Announces $6 Million Public Offering to Advance Immunotherapy and Vaccine Development

GeoVax Labs, Inc., a clinical-stage biotechnology company at the forefront of developing immunotherapies and vaccines for cancer and infectious diseases, has announced a public offering expected to raise approximately $6 million in gross proceeds. The offering involves the sale of about 9.2 million units, each consisting of one share of common stock and warrants, priced at $0.65 per unit. This strategic financial move is poised to bolster the company's working capital and support its general corporate objectives, underscoring its commitment to advancing medical science.

The warrants included in the offering grant the right to purchase up to approximately 18.5 million shares of common stock at the same price, with a five-year term from the issuance date. Roth Capital Partners is serving as the exclusive placement agent for this offering, which is anticipated to close around July 2, 2025, pending standard closing conditions. This development is a testament to GeoVax's ongoing efforts to secure the necessary funding to propel its research and development initiatives forward.

GeoVax's portfolio includes promising candidates like GEO-CM04S1, a next-generation COVID-19 vaccine currently in Phase 2 trials, and Gedeptin®, an oncolytic solid tumor gene-directed therapy. The company is also pioneering a vaccine targeting Mpox and smallpox, with plans to advance directly to a Phase 3 clinical evaluation. These endeavors highlight GeoVax's pivotal role in addressing some of the most pressing health issues of our time, from pandemic preparedness to cancer treatment.

The offering is made possible under a registration statement filed with the Securities and Exchange Commission (SEC), ensuring transparency and compliance with regulatory standards. Interested parties can access detailed information through the SEC's website at http://www.sec.gov, reflecting the company's adherence to open communication and regulatory diligence.

This financial infusion is critical for GeoVax as it navigates the complex landscape of biotechnology development, where innovation and funding are inextricably linked. The company's forward-looking statements underscore the potential of its products to meet unmet medical needs, while also acknowledging the inherent risks and uncertainties of biotech research. As GeoVax continues to push the boundaries of science, this public offering represents a key milestone in its journey to bring transformative therapies to patients worldwide.